Nutrition and health

Objectives:
Despite growing evidence that type 2 diabetes is associated with dementia, the question of whether intensive glucose control can prevent or arrest cognitive decline remains unanswered. Therefore, this review articles (meta-analysis) has been conducted.

Does intensive glucose control slow down cognitive decline in persons with type 2 diabetes?

Study design:
This review article included 5 cohort studies with 16,584 participants.
The mean follow-up duration ranged from 3.5 to 10 years.
The mean age of participants in the studies included in the current meta-analysis was 65.6 years at the initiation of the studies and the proportion of women was 40.8%.
All quality assessment scores fell in the range of 8 or 9, indicating high quality.
There was no publication bias.

Results and conclusions:
The investigators found a significantly poorer decline in cognitive function in the intensive glucose control group [β = -0.03, 95% CI = -0.05 to -0.02] than in the conventional glucose control group.

The investigators found, subgroup analysis showed a significant difference in the change in cognitive performance in composite cognitive function [β = -0.03, 95% CI = -0.05 to -0.01] and memory [β = -0.13, 95% CI = -0.25 to -0.02].

The investigators concluded that intensive glucose control in persons with type 2 diabetes slows down cognitive decline, especially the decline in composite and memory function. The impact of intensive glucose control on the brain structural abnormalities and risk of dementia needs further rigorously designed studies to validate these findings. Also, replicating and validating these findings is warranted.

Original title:
Impact of Intensive Glucose Control on Brain Health: Meta-Analysis of Cumulative Data from 16,584 Patients with Type 2 Diabetes Mellitus by Tang X, Cardoso MA, […], Simó R.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947088/

Additional information of El Mondo:
Find more information/studies on glucose, dementia and diabetes right here.

Objectives:
Excess body weight, including overweight and obesity, is one of the major factors influencing human health and plays an important role in the global burden of disease. Carotenoids serve as precursors of vitamin A-related retinoids and are considered to have potential effects on many diseases. However, the influence of carotenoids on people with excess body weight is unclear. Therefore, this review article has been conducted.

Does carotenoid supplementation reduce risk of overweight and obesity in overweight or obese subjects?

Study design:
This review article included 7 randomized controlled trials (RCTs) and 8 observational studies with 28,944 subjects and data on multiple carotenoid subgroups, including lycopene, astaxanthin, cryptoxanthin, α-carotene, and β-carotene.

In all included RCTs, the intervention duration was 20 days at the shortest and 16 weeks at the longest and the range of intervention doses was 1.2-60 mg/d.

Results and conclusions:
The investigators found that the insufficiency of serum carotenoids significantly increased risk of overweight and obesity with 73% [OR = 1.73, 95% CI = 1.57 to 1.91, p 0.001].

The investigators found, moreover, carotenoid supplementation was significantly associated with body weight reductions [SMD = -2.34 kg, 95% CI = -3.80 to -0.87 kg, p 0.001], body mass index decrease [SMD = -0.95 kg/cm², 95% CI = -1.88 to -0.01 kg/cm², p 0.001] and waist circumference losses [SMD = -1.84 cm, 95% CI = -3.14 to -0.54 cm, p 0.001].

The investigators concluded that 1.2-60 mg/d carotenoid supplementation reduces risk of overweight and obesity in overweight or obese subjects. Furthermore, an insufficiency of serum carotenoids is a risk factor for overweight and obesity. Additional data from large clinical trials are needed.

Original title:
The association between carotenoids and subjects with overweight or obesity: a systematic review and meta-analysis by Yao N, Yan S, […], Cui W.

Link:
https://pubmed.ncbi.nlm.nih.gov/33977977/

Additional information of El Mondo:
Find more information/studies on carotenoid consumption and obesity/overweight right here.

Am I overweight?
 

Objectives:
The evidence on the association between obesity and atrial fibrillation (AF) recurrence was equivocal. Therefore, this review article (meta-analysis) has been conducted.

Does obesity increase risk of atrial fibrillation recurrence in patients undergoing catheter ablation?

Study design:
This review article included 20 studies with 52,771 patients.

Results and conclusions:
The investigators found that obesity was significantly associated with higher atrial fibrillation recurrence [OR = 1.30, 95% C = 1.16 to 1.47, p 0.001, I2 = 72.7%] and similar rate of adverse events [OR = 1.21, 95% CI = 0.87 to 1.67, p = 0.264, I2 = 23.9%] in patients undergoing catheter ablation.

The investigators found meta-regression showed that the association varied by age [coefficient = -0.03, p = 0.024].

The investigators found meta-analysis of highest versus lowest BMI showed that the highest group had higher atrial fibrillation recurrence [OR = 1.37, 95% CI = 1.18 to 1.58, p 0.001, I2 = 64.9%] and adverse events [OR = 2.02, 95% CI = 1.08 to 3.76, p = 0.028, I2 = 49.5%] in patients undergoing catheter ablation.

The investigators found the dose-response relationship for BMI and atrial fibrillation recurrence was nonlinear [p nonlinearity 0.001], the curve became steeper at 30-35 kg/m².

The investigators found for adverse events, an increase of 1% for every 1 kg/m² increase in BMI [OR = 1.01, 95% CI = 1.00 to 1.02, p = 0.001], the relationship was nonlinear [p nonlinearity = 0.001].

The investigators concluded that obesity is associated with higher atrial fibrillation recurrence in patients undergoing catheter ablation. High BMI is associated with a higher risk for adverse events.

Original title:
BMI and atrial fibrillation recurrence post catheter ablation: A dose-response meta-analysis by Pranata R, Henrina J, […], Munawar M.

Link:
https://pubmed.ncbi.nlm.nih.gov/33544873/

Additional information of El Mondo:
Find more information/studies on cardiovascular diseases and obesity/overweight right here.

Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore your heart’s regular rhythm. Catheter ablation is also called radiofrequency ablation.

Am I overweight?
 

Objectives:
A few randomized controlled trials (RCTs) have assessed the effect of brown rice consumption on metabolic parameters (such as, weight, height, waist circumference, fasting glucose, LDL, HDL, total cholesterol, triglycerides and blood pressure) compared to white rice, with inconsistent findings. Therefore, this review article has been conducted.

Is the effect of brown rice on adiposity indices (such as, weight, height and waist circumference), lipid profile (such as, LDL, HDL, total cholesterol and triglycerides) and glycemic markers (such as, fasting blood glucose) higher compared to white rice in adult subjects?

Study design:
This review article included 13 RCTs.
In accordance with Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, the certainly of the included evidence was low and very low.

Results and conclusions:
The investigators found brown rice significantly reduced:
weight by -1.63 kg [95% CI = -2.15 to -1.11, I2 = 97%, n = 6];
body mass index (BMI) by -0.58 kg/m² [95% CI = -0.78 to -0.37, I2 = 96%, n = 6] and;
waist circumference by -2.56 cm [95% CI = -4.86 to -0.26, I2 = 88%, n = 5] compared with white rice.

The investigators found, moreover, brown rice had no significant effect on lipid profile and glycemic markers.

The investigators found pre-germinated brown rice significantly declined:
weight by -1.75 kg [95% CI = -2.70 to -0.81, I2 = 99%, n = 4];
total cholesterol by -24.22 mg/dL [95% CI = -33.03 to -15.41, I2 = 78%, n = 5];
triglyceride (TG) by -43.28 mg/dL [95% CI = -74.05 to -12.50, I2 = 90%, n = 5];
low-density lipoprotein (LDL or bad cholesterol) by -20.05 mg/dL [95% CI = -29.57 to -10.52, I2 = 71%, n = 5] and;
fasting blood glucose (FBG) by -15.83 mg/dL [95% CI = -25.20 to -6.46, I2 = 91%, n = 5] compared to white rice.

The investigators concluded brown rice has anti-obesity effects in comparison with white rice. However, it has no beneficial effects on lipid profile and glycemic markers. Furthermore, pre-germinated brown rice has better functional effects on promoting lipid profile and fasting blood glucose compared to brown rice.

Original title:
The effect of brown rice compared to white rice on adiposity indices, lipid profile, and glycemic markers: a systematic review and meta-analysis of randomized controlled trials by Golzarand M, Toolabi K, […], Mirmiran P.

Link:
https://pubmed.ncbi.nlm.nih.gov/33905269

Additional information of El Mondo:
Find more information/studies on rice consumption and obesity/overweight right here.

Objectives:
Magnesium supplementation is often purported to improve sleep; however, as both an over-the-counter sleep aid and a complementary and alternative medicine, there is limited evidence to support this assertion. Therefore, this review article (meta-analysis) has been conducted.

Does magnesium supplementation improve sleep in older adults with insomnia?

Study design:
This review article included 3 randomized control trials (RCTs), comparing oral magnesium to placebo in 151 older adults in 3 countries.

All 3 RCTs were at moderate-to-high risk of bias and outcomes were supported by low to very low quality of evidence.

Daily elemental magnesium intake ranged from 320 mg to 729 mg taken 2 to 3 times per day using 2 formulations (magnesium oxide and magnesium citrate tablets).
Duration of follow-up for outcome assessment ranged from 20 days to 8 weeks.

Results and conclusions:
The investigators found pooled analysis showed that post-intervention sleep onset latency time was significantly 17.36 min less [95% CI = -27.27 to -7.44, p = 0.0006] after magnesium supplementation compared to placebo.
Significantly because the calculated p-value of = 0.0006 was less than the p-value of 0.05.

The investigators found pooled analysis showed that total sleep time improved by 16.06 min in the magnesium supplementation group but was statistically insignificant [95% CI = - 5.99 to 38.12, p = 0.15].
Insignificant because the calculated p-value of 0.15 was larger than the p-value of 0.05.

The investigators concluded that RCT evidence may support oral magnesium supplements (less than 1 g quantities given up to 3 times a day) for insomnia symptoms in older adults. May support because all 3 RCTs are at moderate-to-high risk of bias and outcomes are supported by low to very low quality of evidence.

Original title:
Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis by Mah J and Pitre T.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053283/

Additional information of El Mondo:
Find more information/studies on magnesium consumption and elderly right here.

Magnesium oxide contains 60% elemental magnesium and magnesium citrate contains 16% elemental magnesium.
So if you want to get 320 mg elemental magnesium from magnesium supplements, you have to take 534 mg magnesium oxide supplements or 2000 mg magnesium citrate.

Objectives:
Several mechanisms have been proposed for the effect of vitamin E on weight loss. Yet various interventional studies with wide ranges of doses and durations have reported contradictory results. Therefore, this review article has been conducted.

Does vitamin E supplementation reduce overweight?

Study design:
This review article included 24 RCTs.

Results and conclusions:
The investigators found there was no significant effect of vitamin E supplements on weight [WMD = 0.15, 95% CI = -1.35 to 1.65, p = 0.847], body mass index (BMI) [WMD = 0.04, 95% CI = -0.29 to 0.37, p = 0.815] and waist circumference (WC) [WMD = -0.19 kg, 95% CI = -2.06 to 1.68, p = 0.842], respectively.

The investigators found, however, subgroup analysis revealed that vitamin E supplementation in studies conducted on participants with normal BMI (18.5-24.9) had increasing impact on BMI [p = 0.047].  

The investigators concluded there is no significant effect of vitamin E supplementation on weight, BMI and waist circumference (WC). However, vitamin E supplementation increases BMI in participants with normal BMI (18.5-24.9).

Original title:
Can vitamin E supplementation affect obesity indices? A systematic review and meta-analysis of twenty-four randomized controlled trials by Emami MR, Jamshidi S, […], Aryaeian N.

Link:
https://pubmed.ncbi.nlm.nih.gov/33632535/

Additional information of El Mondo:
Find more information/studies on vitamin E and obesity/overweight right here.

Objectives:
Lifestyle interventions are an important and viable approach for preventing cognitive deficits. However, the results of studies on alcohol, coffee and tea consumption in relation to cognitive decline have been divergent, likely due to confounds from dose-response effects. Therefore, this review article (meta-analysis) has been conducted.

Does alcohol, coffee or tea consumption reduce the risk of cognitive deficits (such as dementia or Alzheimer's disease)?

Study design:
This review article included 29 prospective cohort studies from America, Japan, China and some European countries (131,777 participants for alcohol, 333,843 participants for coffee and 20,411 participants for tea).

The NOS score was 8.

Results and conclusions:
The investigators found dose-response relationships showed that compared to non-drinkers, low consumption (11 g/day) of alcohol significantly reduced the risk of cognitive deficits or only dementias, but there was no significant effect of heavier drinking (>11 g/day).

The investigators found dose-response relationships showed that compared to non-drinkers, low consumption of coffee significantly reduced the risk of any cognitive deficit (2.8 cups/day) or dementia (2.3 cups/day).
However, coffee drinking was not a significant protective factor for cognitive deficits in groups of average age 60 years.

The investigators found dose-response relationships showed that compared to non-drinkers, every cup of green tea per day significantly reduced risk of cognitive deficits with 6% [relative risk = 0.94, 95% CI = 0.92 to 0.97].  

The investigators concluded that light consumption of alcohol (11 g/day) and coffee (2.8 cups/day) reduces risk of cognitive deficits. Cognitive benefits of green tea consumption increases with the daily consumption.

Original title:
Alcohol, coffee and tea intake and the risk of cognitive deficits: a dose-response meta-analysis by Ran LS, Liu WH, […], Wang W.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061189/

Additional information of El Mondo:
Find more information/studies on alcohol, coffee and tea consumption and dementia right here.

Objectives:
Do magnesium intakes reduce risk of all-cause, cancer and cardiovascular disease (CVD) mortality?

Study design:
This review article included 19 prospective cohort studies with a total of 1,168,756 participants (52,378 deaths from all causes (all-cause mortality), 23,478 from cardiovascular disease (CVD) and 11,408 from cancer).
The follow-up period was 3.5 to 32 years.

Results and conclusions:
The investigators found dietary magnesium intake was significantly associated with a lower risk of 13% for all-cause mortality [pooled effect size (ES) = 0.87, 95% CI = 0.79 to 0.97, p = 0.009, I2 = 70.7%, p 0.001].

The investigators found dietary magnesium intake was significantly associated with a lower risk of 20% for cancer mortality [pooled ES = 0.80, 95% CI = 0.67 to 0.97, p = 0.023, I2 = 55.7%, p = 0.027].

The investigators found for supplemental and total magnesium intakes, no significant associations with risks of all-cause, cardiovascular disease and cancer mortality.

The investigators found, however, linear dose-response meta-analysis indicated that each additional intake of 100 mg/d of dietary magnesium was significantly associated with a 6% and 5% reduced risk of all-cause and cancer mortality, respectively.

The investigators concluded that higher intake of dietary magnesium (at least 100 mg/d of dietary magnesium) is associated with a reduced risk of all-cause and cancer mortality, but not cardiovascular disease mortality. Supplemental and total magnesium intakes are not associated with the risk of all-cause, cardiovascular disease and cancer mortality. These findings indicate that consumption of magnesium from dietary sources may be beneficial in reducing all-cause and cancer mortality and thus have practical importance for public health.  

Original title:
Total, Dietary, and Supplemental Magnesium Intakes and Risk of All-Cause, Cardiovascular, and Cancer Mortality: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies by Bagheri A, Naghshi S, […], Esmaillzadeh A.

Link:
https://pubmed.ncbi.nlm.nih.gov/33684200/

Additional information of El Mondo:
Find more information/studies on magnesium consumption, cardiovascular disease and cancer right here.

Objectives:
Previous population studies on the associations between dietary fatty acids (FAs), plasma FAs levels and the risk of age-related macular degeneration (AMD) have yielded inconclusive results. Therefore, this review article (meta-analysis) has been conducted.

Do higher dietary fatty acids (EPA and DHA) intakes or higher plasma fatty acids levels reduce risk of age-related macular degeneration?

Study design:
This review article included 11 prospective cohort studies with 167,581 participants. During the follow-up periods (ranging from 3 to 28 years), 6,318 cases of age-related macular degeneration were recorded.

Results and conclusions:
The investigators found that each 1 g/day increment of dietary intake of docosahexaenoic acid (DHA) and eicosatetraenoic acid (EPA) combined significantly reduced risk of early age-related macular degeneration with 33% [RR = 0.67, 95% CI = 0.51 to 0.88].
Significantly means that there is an association with a 95% confidence.

The investigators found that each 1 g/day increment of dietary intake of docosahexaenoic acid (DHA) significantly reduced risk of early age-related macular degeneration with 50% [RR = 0.50, 95% CI = 0.32 to 0.78].
Significantly means it can be said with a 95% confidence that each 1 g/day increment of dietary intake of docosahexaenoic acid (DHA) really reduces risk of early age-related macular degeneration with 50%.

The investigators found that each 1 g/day increment of dietary intake of eicosatetraenoic acid (EPA) significantly reduced risk of early age-related macular degeneration with 60% [RR = 0.40, 95% CI = 0.18 to 0.87].
Significantly because RR of 1 was not found in the 95% CI of 0.18 to 0.87. RR of 1 means no risk/association.

The investigators found that higher plasma docosahexaenoic acid (DHA) levels significantly reduced risk of advanced age-related macular degeneration with 28% [RR = 0.72, 95% CI = 0.55 to 0.95].

The investigators found that higher plasma eicosatetraenoic acid (EPA) levels significantly reduced risk of advanced age-related macular degeneration with 43% [RR = 0.57, 95% CI = 0.40 to 0.81].

The investigators concluded that 1 g/day of dietary intake DHA and 1 g/day of dietary intake EPA and higher plasma DHA and EPA levels are associated with a reduced risk of age-related macular degeneration.

Original title:
Dietary fatty acid intake, plasma fatty acid levels, and the risk of age-related macular degeneration (AMD): a dose-response meta-analysis of prospective cohort studies by Zhong Y, Wang K, [...], Yao K.

Link:
https://pubmed.ncbi.nlm.nih.gov/33469697/

Additional information of El Mondo:
Find more information/studies on EPA en DHA and elderly right here.

A high plasma EPA and DHA content can be obtained by eating a lot of oily fish and/or by taking EPA and DHA supplements (fish oil supplements).
Oily fish contains more EPA and DHA than non-oily fish.

Early age-related macular degeneration: most people do not experience adverse symptoms or vision loss in the early stage of age-related macular degeneration, but night vision problems are often reported. Though no pigmentary abnormalities are apparent upon examination, medium-sized drusen (>63 μm and ≤125 μm) are present.

Objectives:
Previous studies on the association between alcohol intake and risk of fracture have reached conflicting findings. Therefore, this review article has been conducted.

Does alcohol consumption increase risk of fractures?

Study design:
This review article included 38 prospective cohort studies with a total sample size of 5,053,117 participants and 169,560 cases of fracture.

Results and conclusions:
The investigators found in a random-effects meta-analysis, that alcohol consumption significantly increased risk of total fractures with 35% [RR = 1.35, 95% CI = 1.01 to 1.81] and any fractures with 24% [RR= 1.24, 95% CI = 1.11 to 1.38].
Significant because RR of 1 was not found in the 95% CI of 1.01 to 1.81. RR of 1 means no risk/association.

The investigators found, however, no significant association between alcohol intake and risk of hip fractures [RR = 1.19, 95% CI = 0.96 to 1.48], osteoporotic fractures [RR = 2.01, 95% CI = 0.76 to 5.34], vertebral fractures [RR = 0.98, 95% CI = 0.68 to 1.40] and wrist fractures [RR = 0.99, 95% CI = 0.85 to 1.16].
No significant because RR of 1 was found in the 95% CI of 0.85 to 1.06. RR of 1 means no risk/association.

The investigators concluded that alcohol consumption is positively associated with risk of total fractures and any fractures.

Original title:
A systematic review and meta-analysis of prospective cohort studies on the association between alcohol intake and risk of fracture by Asoudeh F, Salari-Moghaddam A, […], Esmaillzadeh A.

Link:
https://pubmed.ncbi.nlm.nih.gov/33596741/

Additional information of El Mondo:
Find more information/studies on alcohol and osteoporosis right here.
 

Objectives:
Recent evidence suggests that diet can modify the risk of future cognitive impairment and dementia. A biologically plausible rationale and initial clinical data indicate that the antioxidant activities of dietary carotenoids may assist the preservation of cognitive function. Therefore, this review article has been conducted.

Does carotenoid supplementation improve cognitive performance among healthy adults?

Study design:
This review article included 9 RCTs, involving 2,228 subjects in the treated group (group with carotenoid supplementation) and 2,174 subjects in control group (group without carotenoid supplementation).
The age of all participants varied from 45 to 78 years.
The majority of clinical trials assessed the effect of xanthophylls such as lutein, zeaxanthin, and astaxanthin, whereas only 1 study determined the effects of β-carotene.
The duration of carotenoid supplementation ranged from 2 weeks to 12 months.
The dosage of carotenoids administered in the studies ranged from 0.5 mg/d to 50 mg/d.
There was no evidence of publication bias.

Results and conclusions:
The investigators found results of the pooled meta-analysis showed a significant effect of carotenoid intervention on cognitive outcomes [Hedge's g = 0.14, 95% CI = 0.08 to 0.20, p 0.0001, I2 = 0.00%].
The sensitivity analysis did not change the overall findings obtained from the primary analysis.

The investigators concluded that these results highlight the potential role of carotenoids (0.5 mg/d to 50 mg/d) in the protection of mental functions even in subjects (healthy participants aged 45-78 years) without cognitive impairment. This is particularly important because the population is aging and preservation of cognitive function is crucial for individual autonomy and quality of life, even in non-demented subjects. Further well-powered and long-term trials are required to determine treatment duration, type of carotenoid and optimal dosage.

Original title:
Carotenoids and Cognitive Outcomes: A Meta-Analysis of Randomized Intervention Trials by Davinelli S, Ali S, […], Corbi G.

Link:
https://www.mdpi.com/2076-3921/10/2/223/htm

Additional information of El Mondo:
Find more information/studies on carotenoids and dementia right here.
 

Objectives:
Recent systematic reviews and meta-analyses of randomized, double-blind, placebo-controlled trials (double-blind, placebo-controlled RCTs) have reported controversial findings regarding the associations between calcium supplements on the risk of cardiovascular disease (CVD). Therefore, this review article has been conducted.

Do calcium supplements increase risk of cardiovascular disease (CVD)?

Study design:
This review article included 13 RCTs with 28,935 participants in an intervention group (group with calcium supplements) and 14,243 in a control group (group without calcium supplements).

The mean age of the study participants was 66.3 years (range: 35 to 97 years) and 92.8% of those were women.
Publication bias was not observed.

Results and conclusions:
The investigators found calcium supplements significantly increased the risk of cardiovascular disease with 15% in healthy postmenopausal women [RR = 1.15, 95% CI = 1.06 to 1.25, I2 = 0.0%, n = 14].

The investigators found calcium supplements significantly increased the risk of coronary heart disease with 16% in healthy postmenopausal women [RR = 1.16, 95% CI = 1.05 to 1.28, I2 = 0.0%, n = 9].

The investigators found in the subgroup meta-analysis, dietary calcium intake of 700-1000 mg per day or supplementary calcium intake of 1000 mg per day significantly increased the risk of cardiovascular disease and coronary heart disease.

The investigators concluded that the use of calcium supplements (1000 mg per day) is significantly associated with the increased risk of cardiovascular disease and coronary heart disease by 15%, specifically in postmenopausal women. These findings should be explicitly confirmed by conducting further RCTs with cardiovascular disease outcome measures as well as the incidence of osteoporosis or fractures as the primary endpoints.

Original title:
Calcium Supplements and Risk of Cardiovascular Disease: A Meta-Analysis of Clinical Trials by Myung SK, Kim HB, […], Oh SW.

Link:
https://pubmed.ncbi.nlm.nih.gov/33530332/

Additional information of El Mondo:
Find more information/studies on calcium consumption, elderly and cardiovascular diseases right here.

Objectives:
Vitamin D deficiency during pregnancy or infancy is associated with adverse growth in children. No systematic review has been conducted to summarize available evidence on the effect of vitamin D supplementation in pregnancy and infancy on growth and body composition in children. Therefore, this review article has been conducted.

Does vitamin D supplementation during pregnancy or infancy increase adiposity (severe or morbid overweight) risk in childhood?

Study design:
This review article included 12 RCTs with a total of 4,583 participants.
The doses of vitamin D in the intervention group (group with vitamin D supplements) were 60,000 IU/4 weeks (1,500 mcg/4 weeks) or 60,000 IU/8 weeks and in the control group (group without vitamin D supplements) was 400 IU/day.

Results and conclusions:
The investigators found vitamin D supplementation during pregnancy was associated with higher triceps skinfold thickness (mm) [MD = 0.33, 95% CI = 0.12 to 0.54, I2 = 34%] in neonates.

The investigators found vitamin D supplementation during pregnancy or infancy was associated with significantly increased length for age z-score in infants at 1 year of age [MD = 0.29, 95% CI = 0.03 to 0.54, I2 = 0%].

The investigators found vitamin D supplementation during pregnancy or infancy was associated with lower body mass index (BMI) (kg/m²) [MD = -0.19, 95% CI = -0.34 to -0.04, I2 = 0%] and body mass index z-score (BMIZ) [MD = -0.12, 95% CI = -0.21 to -0.04, I2 = 0%] in offspring at 3-6 years of age.

The investigators found vitamin D supplementation during early life was not observed to be associated with children’s bone, lean or fat mass.

The investigators concluded vitamin D supplementation during pregnancy or infancy is associated with reduced adiposity (severe or morbid overweight) in childhood. Future large well-designed double blinded RCTs are needed to assess the effectiveness of vitamin D supplementation in early life on children’s bone health, lean mass and adiposity.

Original title:
Effect of Vitamin D Supplementation in Early Life on Children's Growth and Body Composition: A Systematic Review and Meta-Analysis of Randomized Controlled Trials by Ma K, Wei SQ, [...], Wen SW.

Link:
https://www.mdpi.com/2072-6643/13/2/524/htm

Additional information of El Mondo:
Find more information/studies on vitamin D and obesity/overweight right here.

Objectives:
Increasing macular pigment optical density (MPOD) as a result of increased macular concentration of lutein and zeaxanthin may reduce the risk of age-related macular degeneration (AMD). Therefore, this review article has been conducted.

Have daily egg consumption beneficial effects on macular pigment optical density and serum lutein levels?

Study design:
This review article included 5 RCTs with a total of 296 participants.
There was no heterogeneity between studies.

Results and conclusions:
The investigators found that egg consumption significantly increased macular pigment optical density [WMD = +0.037, 95% CI = 0.004 to 0.069, p = 0.027] and serum lutein levels [WMD = +0.150 μmol/L, 95% CI = 0.037 to 0.263, p = 0.009].

The investigators found subgroup analyses showed that egg consumption had a larger effect on macular pigment optical density in studies with a parallel design and increased serum lutein levels to a greater extent in a healthy population.

The investigators concluded daily egg consumption have beneficial effects on macular pigment optical density and serum lutein level is inversely associated with reduced age-related macular degeneration progression. Further clinical trials are required to confirm the results of this review article.

Original title:
A positive effect of egg consumption on macular pigment and healthy vision: a systematic review and meta-analysis of clinical trials by Sikaroudi MK, Saraf-Bank S, […], Soltani S.

Link:
https://pubmed.ncbi.nlm.nih.gov/33491232/

Additional information of El Mondo:
Find here more information/studies about review article/significant, egg consumption and elderly diseases.
 

Objectives:
Does a high dietary intake of β-cryptoxanthin reduce the risk of osteoporosis and hip fracture?

Study design:
This review article included 7 cohort studies, 4 case-control studies and 4 cross-sectional studies with a total of 100,496 individuals.
The methodological qualities of all studies were rated as “fair” to “good”.
The number of populations in each study ranged from 59 to 25,566.

Results and conclusions:
The investigators found that a high dietary intake of β-cryptoxanthin significantly reduced risk of osteoporosis with 24% [OR = 0.76, 95% CI = 0.66 to 0.88, p = 0.0002, I2 = 36%, p = 0.11].

The investigators found in subgroup analysis that a high dietary intake of β-cryptoxanthin significantly reduced risk of osteoporosis with 28% [OR = 0.72, 95% CI = 0.58 to 0.91, p = 0.005, I2 = 59%] among women.

The investigators found in subgroup analysis that a high dietary intake of β-cryptoxanthin significantly reduced risk of osteoporosis with 20% [OR = 0.80, 95% CI = 0.65 to 1.00, p = 0.005, I2 = 11%] among men.

The investigators found that a high dietary intake of β-cryptoxanthin significantly reduced risk of hip fracture with 28% [OR = 0.72, 95% CI = 0.60 to 0.87, p = 0.0008, I2 = 55%].

The investigators found in subgroup analysis that a high dietary intake of β-cryptoxanthin significantly reduced risk of hip fracture with 29% [OR = 0.71, 95% CI = 0.54 to 0.94, p = 0.02, I2 = 71%] among women. 

The investigators concluded that a high dietary intake of β-cryptoxanthin reduces the risk of osteoporosis and hip fracture. Further longitudinal studies are needed to validate the causality of current findings.

Original title:
Effects of β-Cryptoxanthin on Improvement in Osteoporosis Risk: A Systematic Review and Meta-Analysis of Observational Studies by Kim SJ, Anh NH, […], Kwon SW.

Link:
https://www.mdpi.com/2304-8158/10/2/296/htm

Additional information of El Mondo:
Find more information/studies on β-cryptoxanthin and osteoporosis right here.
 

Objectives:
Is there a causal relationship between dairy products or calcium supplements and the reduction in fat mass and BMI among overweight or obese adults?

Study design:
This review article included 10 and 14 RCTs with ≥ 12 weeks interventions of calcium supplements and dairy products among overweight (BMI>25) or obese (BMI>30) adults aged ≥18.

Results and conclusions:
The investigators found that dairy products significantly reduced fat mass among overweight or obese adults [SMD = -0.40, 95% CI = -0.77 to -0.02].
This reduction was also significant in the analysis of RCTs with low risk of bias scores.

The investigators found that dairy products significantly reduced BMI among overweight or obese adults [SMD = -0.46 kg/m², 95% CI = -0.67 to -0.26].
This reduction was also significant in the analysis of RCTs with low risk of bias scores.

The investigators found that calcium supplements significantly reduced fat mass among overweight or obese adults [SMD = -0.15, 95% CI = -0.28 to -0.02].
However, this reduction was not significant in the analysis of RCTs with low risk of bias scores.

The investigators concluded there is a causal relationship between dairy products without distinction of fat percentage and the reduction in fat mass and BMI among overweight or obese adults.

Original title:
Meta-analysis of randomized controlled trials on calcium supplements and dairy products for changes in body weight and obesity indices by Hong JY, Lee JS, [...], Kim MK.

Link:
https://pubmed.ncbi.nlm.nih.gov/33292017/

Additional information of El Mondo:
Find more information/studies on dairy product and calcium consumption and obesity/overweight right here.

Objectives:
Do omega-3 fatty acid supplements (EPA and DHA) improve sarcopenia-related performances among the elderly?

Study design:
This review article included 10 RCTs with 552 participants.
The number of study participants ranged from 24 to 126 and the durations of the interventions spanned 10 to 24 weeks.
The doses ranged from 0.16 to 2.6 g/day of EPA and from 0 to 1.8 g/day of DHA.
The mean ages of the participants across the RCTs ranged from 63 to 75 years old.

Results and conclusions:
The investigators found in subgroup analyses that omega-3 fatty acid supplements (EPA and DHA) at more than 2 g/day significantly increased muscle mass among the elderly [SMD = 0.67 kg, 95% CI = 0.16 to 1.18, p 0.05].

The investigators found in subgroup analyses that omega-3 fatty acid supplements (EPA and DHA) during more than 6 months significantly improved walking speed among the elderly [SMD = 1.78 m/sec, 95% CI = 1.38 to 2.17, p 0.05].

The investigators concluded that taking at least 2 grams of omega-3 supplements (EPA and DHA) per day increases muscle mass among the elderly, while taking omega-3 supplements for at least 6 months increases walking speed among the elderly.

Original title:
Effects of Omega-3 Fatty Acids on Muscle Mass, Muscle Strength and Muscle Performance among the Elderly: A Meta-Analysis by Huang YH, Chiu WC, […], Wang YH.

Link:
https://www.mdpi.com/2072-6643/12/12/3739/htm

Additional information of El Mondo:
Find more information/studies on EPA and DHA consumption and elderly right here.
EPA and DHA are present in fish.
 

Objectives:
Does pistachio supplementation reduce obesity risk?

Study design:
This review article included 11 randomized controlled trials (RCTs) with 1,593 subjects.

The assigned pistachio intake was below 50 g/d in 3 studies.
Intervention times were shorter than 12 weeks in 4 studies.
There was no significant publication bias.

Results and conclusions:
The investigators found compared to the control diet group, the pistachio supplementation regimen significantly decreased BMI [-0.18 kg/m², 95% CI = -0.26 to -0.11 kg/m², p 0.001, I2 = 29.8%, p = 0.180].

The investigators found compared to the control diet group, the pistachio supplementation regimen did not significantly change waist circumference [net change = 0.76 cm, 95% CI = -0.11 to 1.63 cm, p = 0.087, I2 = 7.0%, p = 0.340].

The investigators found compared to the control diet group, the pistachio supplementation regimen had no effect on body weight [net change = 0.22 kg, 95% CI = -0.50 to 0.07 kg, p = 0.141, I2 = 0.0%, p = 0.962].

The investigators concluded compared to a controlled dietary intake, an adequate amount of pistachio supplementation lowers BMI without increasing body weight, which supports the view that pistachio consumption is beneficial for human health.

Original title:
The relationship between pistachio (Pistacia vera L) intake and adiposity: A systematic review and meta-analysis of randomized controlled trials by Xia K, Yang T, […], Chen XZ.

Link:
https://journals.lww.com/md-journal/Fulltext/2020/08210/The_relationship_between_pistachio__Pistacia_vera.7.aspx

Additional information of El Mondo:
Find more information/studies on nut consumption and obesity/overweight right here.

Objectives:
Does calcium combined with vitamin D supplementation reduce risk of osteoporosis in postmenopausal women?

Study design:
This review article included 10 RCTs.

Results and conclusions:
The investigators found calcium combined with vitamin D supplementation significantly increased total bone mineral density [SMD = 0.537, 95% CI = 0.227 to 0.847] in postmenopausal women.

The investigators found calcium combined with vitamin D supplementation significantly increased lumbar spine bone mineral density [SMD = 0.233, 95% CI = 0.073 to 0.392, p 0.001] in postmenopausal women.

The investigators found calcium combined with vitamin D supplementation significantly increased arms bone mineral density [SMD = 0.464, 95% CI = 0.186 to 0.741] in postmenopausal women.

The investigators found calcium combined with vitamin D supplementation significantly increased femoral neck bone mineral density [SMD = 0.187, 95% CI = 0.010 to 0.364] in postmenopausal women.

The investigators found calcium combined with vitamin D supplementation significantly reduced risk of hip fracture with 13.6% [RR = 0.864, 95% CI = 0.763 to 0.979] in postmenopausal women.

The investigators found in subgroup analysis that calcium combined with 400 IU/d (10 mcg/d) vitamin D supplementation significantly increased femoral neck bone mineral density [SMD = 0.335, 95% CI = 0.113 to 0.558] in postmenopausal women.

The investigators found in subgroup analysis that dairy products fortified with calcium and vitamin D significantly increased total bone mineral density [SMD = 0.784, 95% CI = 0.322 to 1.247] in postmenopausal women.

The investigators found in subgroup analysis that dairy products fortified with calcium and vitamin D significantly increased lumbar spine bone mineral density [SMD = 0.320, 95% CI = 0.146 to 0.494] in postmenopausal women.

The investigators concluded that dairy products fortified with calcium and vitamin D have a favourable effect on bone mineral density. Furthermore, calcium combined with vitamin D supplementation could prevent osteoporosis hip fracture in postmenopausal women.

Original title:
Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials by Liu C, Kuang X […], Li D.

Link:
https://pubmed.ncbi.nlm.nih.gov/33237064/

Additional information of El Mondo:
Find more information/studies on dairy products consumption, calcium and vitamin D right here.

Objectives:
There are numerous trials reported the effect of alpha-lipoic acid (ALA) on obesity measurements; while no summarised dose-response meta-analysis is available to address the effects of dose and duration of ALA supplementation on obesity measurements. Therefore, this review article has been conducted.

Does alpha-lipoic acid supplementation improve obesity measurements including weight, body mass index (BMI), waist circumference (WC), waist to hip ratio (WHR) and fat mass (FM)?

Study design:
This review article included 18, 21 and 8 RCTs of ALA-weight, ALA-BMI, ALA-WC, respectively.

Results and conclusions:
The investigators found in two-class meta-analysis, alpha-lipoic acid supplementation significantly reduced weight [WMD = -2.29 kg, 95% CI = -2.98 to -1.60, p 0.01] and BMI [WMD = -0.49 g/m², 95% CI = -0.83 to -0.15, p = 0.005] but had no effect on waist circumference [WMD = -2.57 cm, 95% CI = -8.91 to 3.76, p = 0.426].

The investigators found while the dose-response meta-analysis revealed that the duration of alpha-lipoic acid supplementation was a significant factor affecting waist circumference reduction [p non-linearity = 0.047].
While no evidence of departure from linearity was observed for other variables; moreover, subgrouping also revealed that gender could be an important factor affecting the alpha-lipoic acid impact on waist circumference, which was significant among women [WMD = -4.099, 95%CI = -7.837 to -0.361, p = 0.032].

The investigators concluded that alpha-lipoic acid supplementation reduces BMI, weight in a two-class meta-analysis without evidence of departure from linearity in terms of dose or duration. While the association of alpha-lipoic acid supplementation on waist circumference is dependent to the duration of the study. Although further trials evaluating the other obesity measurements specially central obesity will be helpful to infer a more reliable result.

Original title:
Alpha-lipoic acid supplementation significantly reduces the risk of obesity in an updated systematic review and dose response meta-analysis of randomised placebo-controlled clinical trials by Vajdi M and Farhangi MA.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/32091656

Additional information of El Mondo:
Find more information/studies on fat and obesity/overweight right here.

Objectives:
Isoflavones have a structure similar to 17β-estradiol, so they may be useful to postmenopausal women in preventing bone loss related to estrogen deficiency. Therefore, this review article has been conducted.

Do isoflavone supplements increase bone mineral density (BMD) in postmenopausal women?

Study design:
This review article included 63 RCTs, involving 6,427 postmenopausal women.

Isoflavone interventions were generally safe and well tolerated.

Results and conclusions:
The investigators found statistically significant differences in bone mineral density at the last follow-up visit between the two groups (isoflavones vs. control) at the lumbar spine [MD = 21.34 mg/cm², 95% CI = 8.21 to 34.47 mg/cm², p = 0.001], the femoral neck [MD = 28.88 mg/cm², 95% CI = 15.05 to 42.71 mg/cm², p 0.0001] and the distal radius [MD = 19.27 mg/cm², 95% CI = 5.65 to 32.89 mg/cm², p = 0.006].
This improved bone mineral density was found for genistein 54 mg/day and ipriflavone (a synthetic isoflavone) 600 mg/day.

The investigators concluded isoflavone interventions, genistein (54 mg/day) and ipriflavone (600 mg/day) in particular, have beneficial effects on bone mineral density outcomes and are safe in postmenopausal women. They may be considered as a complementary or alternative option in the prevention and treatment of menopause-related osteoporosis.

Original title:
Effects of Isoflavone Interventions on Bone Mineral Density in Postmenopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials by Sansai K, Takuathung MN, [...], Koonrungsesomboon N.

Link:
https://pubmed.ncbi.nlm.nih.gov/32524173/

Additional information of El Mondo:
Find more information/studies on isoflavones and elderly right here.

Objectives:
Has oral supplementation of vitamin B (vitamins B1, B6, B12 and folic acid alone or combined) preventive effect on cognitive decline in cognitively unimpaired individuals?

Study design:
This review article included 20 RCTs, ranging from 23 to 2,919 participants per study, with a total of 12,697 participants.
8 of these 20 RCTs were deemed appropriate for the meta-analysis.

Results and conclusions:
The investigators found meta-analysis did not yield a significant overall effect of supplementation with vitamin B on cognitive function [SMD = 0.02, 95% CI = -0.034 to 0.08]. A sensitivity analysis focusing on specific risk factors did not alter this result.
Some studies reported isolated significant effects of the intervention on secondary outcomes. However, these findings were outnumbered by the number of cognitive tests that did not yield significant effects.

The investigators concluded there is no overall evidence that oral vitamin B supplementation prevent cognitive decline in cognitively unimpaired individuals. The results of this review do not provide evidence that population groups with certain risk factors would profit more from the intervention than others.

Original title:
Vitamin B-Can It Prevent Cognitive Decline? A Systematic Review and Meta-Analysis by Behrens A, Graessel E, [...], Donath C.

Link:
https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-020-01378-7

Additional information of El Mondo:
Find more information/studies on vitamins B1, B6, B12 and folic acid and dementia right here.

Objectives:
Does coenzyme Q10 supplementation reduce body weight and body mass index (BMI) of patients in randomized controlled clinical trial studies (RCTs)?

Study design:
This review article included 17 RCTs.

Results and conclusions:
The investigators found results of random-effect size meta-analysis showed that supplementation with coenzyme Q10 had no significant decreasing effects on body weight [WMD = 0.28 kg, 95% CI = -0.91 to 1.47, p = 0.64] and BMI [WMD = -0.03, 95% CI = -0.4 to 0.34, p = 0.86] of study participants.
No significant because the calculated p-value of 0.64 was larger than the p-value of 0.05.
Subgroup analysis revealed that dosage of Q10 and trial duration could not differ the results of Q10 supplementation.

The investigators concluded that coenzyme Q10 supplementation has no decreasing effects on body weight and BMI.

Original title:
Effect of Q10 supplementation on body weight and body mass index: A systematic review and meta-analysis of randomized controlled clinical trials by Saboori S, Rad EY, […], Falahi E.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/31336462

Additional information of El Mondo:
Find more information/studies on RCTs/subgroup analysis, coenzyme Q10 and obesity/overweight right here.

Objectives:
Previous studies did not draw a consistent conclusion about the effects of vitamin K combined with vitamin D on human skeletal quality. Therefore, this review article has been conducted.

Does vitamin K combined with vitamin D supplementation increase bone mineral density (BMD)?

Study design:
This review article included 8 RCTs with a total of 971 participants.

Results and conclusions:
The investigators found vitamin K combined with vitamin D supplementation significantly increased total bone mineral density (BMD) [pooled effect size = 0.316, 95% CI = 0.031 to 0.601].

The investigators found vitamin K combined with vitamin D supplementation significantly decreased levels of undercarboxylated osteocalcin [effect size = -0.945, 95% CI = -1.113 to -0.778].

The investigators found simultaneously, subgroup analysis showed that K2 or vitamin K (not specified) supplement less than 500 μg/d, when combined with vitamin D significantly increased total bone mineral density compared with the control group fed a normal diet or the group with no treatment [effect size = 0.479, 95% CI = 0.101 to 0.858 and effect size = 0.570, 95% CI = 0.196 to 0.945, respectively).

The investigators concluded the combination of vitamin K and D supplement increases the total bone mineral density (BMD) and decreases levels of undercarboxylated osteocalcin and a more favorable effect is expected when less than 500 μg/d vitamin K2 is used.

Original title:
The combination effect of vitamin K and vitamin D on human bone quality: a meta-analysis of randomized controlled trials by Kuang X, Liu C, […], Li D.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/32219282

Additional information of El Mondo:
Find more information/studies on elderly, vitamin D and K right here.

Undercarboxylated osteocalcin represents inadequately carboxylated osteocalcin and this fraction increases with vitamin K insufficiency.

Objectives:
Is there a causal relationship between dietary intake of dairy products and a positive effect on bone mineral density (BMD) in healthy postmenopausal women?

Study design:
This review article included 6 RCTs with a total of 618 participants. Milk was the main dairy product used in the trials.

Results and conclusions:
The investigators found there was a significant association between dairy product consumption and bone mineral density of the lumbar spine [SMD = 0.21, 95% CI = 0.05 to 0.37, p = 0.009], femoral neck [SMD = 0.36, 95% CI = 0.19 to 0.53, p  0.001], total hip [SMD = 0.37, 95% CI = 0.20 to 0.55, p  0.001] and total body [SMD = 0.58, 95% CI = 0.39 to 0.77, p  0.001].

The investigators found subgroup analysis showed a positive effect of dairy product consumption on the bone mineral density of the total hip starting from 12 months and the femoral neck starting from 18 months. There was also a positive association with the bone mineral density in the 4 sites in people living in low-calcium intake countries.

The investigators concluded that there is a causal relationship between dietary intake of dairy products, particularly milk during at least 12 months and a positive effect on bone mineral density (BMD) in healthy postmenopausal women. Therefore, dairy product consumption should be considered an effective public health measure to prevent osteoporosis in postmenopausal women.

Original title:
Effects of dairy products on bone mineral density in healthy postmenopausal women: a systematic review and meta-analysis of randomized controlled trials by Shi Y, Zhan Y, [...], Jiang Y.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/32185512

Additional information of El Mondo:
Find more information/studies on dairy products and elderly right here.

Menopause is the point when a woman no longer has menstrual periods for at least 12 months. Postmenopause is the stage after menopause.